The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Relationship of pharmacokinetics (PK), toxicity, and initial evidence of clinical activity with IMGN853, a folate receptor alpha (FRa) targeting antibody drug conjugate in patients (Pts) with epithelial ovarian cancer (EOC) and other FRa-positive solid tumors.
Kathleen N. Moore
No relevant relationships to disclose
Joseph Ponte
Employment or Leadership Position - Immunogen
Stock Ownership - Immunogen
Patricia LoRusso
Employment or Leadership Position - Karmanos Cancer Institute
Michael J. Birrer
No relevant relationships to disclose
Todd Michael Bauer
No relevant relationships to disclose
Hossein Borghaei
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb; Genentech
Research Funding - Arisaph Pharmaceuticals; Millennium; Pfizer
David M. O'Malley
No relevant relationships to disclose
Rodrigo Ruiz-Soto
Employment or Leadership Position - Immunogen
Stock Ownership - Immunogen
Robert Lutz
Employment or Leadership Position - Immunogen
Stock Ownership - Immunogen
Research Funding - Immunogen
Laeeq Malik
No relevant relationships to disclose